A Clinical Study of GK02 in Malignant Ascites

NCT07378436 | Recruiting Early Phase 1

• 1 other identifier: GK02-GBIIT
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 1

Brief Summary

A single-arm, single-center, open-label clinical study comprising three cohorts, evaluating the safety, preliminary efficacy, and pharmacokinetic/ pharmacodynamic (PK/PD) characteristics of autologous tumor-reactive T cells (GK02) derived from malignant ascites caused by advanced solid tumors. The trial initially plans to enroll 9 subjects with malignant ascites caused by advanced solid tumors.

Conditions

Malignant Ascites Caused by Advanced Solid Tumors

Keywords

Advanced solid tumor; Malignant ascites; Gastric cancer

Outcome Measures

Primary Outcomes (2)

• Incidence of AEs

  Incidence and severity of AEs, including but not limited to vital signs, physical examination, laboratory tests. All AEs will be classified as Grades 1 through 5 as defined by NCI CTCAE v5.0.

  12 months

• Incidence of DLTs

  Number of DLTs (dose limiting toxicities) during the first 28 days after the administrations of GK02 in each cohort.

  28 days

Secondary Outcomes (3)

• Changes in the volume of malignant ascites

  12 months

• PuFS

  12 months

• OS

  12 months

Other Outcomes (4)

• Count of TCR copies

  12 months

• Concentration of Cytokines

  12 months

• Percentage of Lymphocyte subsets

  12 months

Study Arms (1)

Tumor-reactive T cells-GK02

EXPERIMENTAL

Treatment with autologous tumor-reactive T cells (GK02) derived from malignant ascites caused by advanced solid tumors.

Drug: GK02

Interventions

GK02 DRUG

Autologous tumor-reactive T cells

Tumor-reactive T cells-GK02

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Ability to understand and sign a written informed consent document；
• At the date of signing ICF, 18 \~75 years old, male or female；
• Patients with advanced solid tumors confirmed by histology or pathology to have failed at least second-line treatment (treatment failure is defined as progression after treatment or intolerance after treatment), including but not limited to gastric cancer, colorectal cancer, pancreatic cancer, ovarian cancer, etc.；
• Pathological diagnosis or clinical diagnosis of malignant ascites, and the researcher determines that treatment for malignant ascites is necessary; During screening, the ascites volume was confirmed to be above the medium level by ultrasound (the maximum depth of ascites in the supine position was ≥3.0cm, and the total volume was ≥500ml);
• ECOG 0-2 points;
• Adequate organ functions;
• There are no absolute or relative contraindications for puncture；
• No peritoneal treatment for malignant ascites has been carried out within 14 days prior to the collection of malignant ascites;
• Female of childbearing age who have a negative urine pregnancy test during the screening period and agree to take effective contraceptive measures for at least 6 months after perfusion; Male subjects whose partners are fertile must agree to use effective contraceptive methods and avoid sperm donation for at least six months after perfusion.

You may not qualify if:

• Those with a history of severe allergies or allergic reactions to any components of the drugs to be used in this study, including but not limited to NMA-LD drugs, contrast agents and contrast agents used in imaging examinations, excipients such as dimethyl sulfoxide (DMSO) and antibiotics in cell products;
• Central nervous system (CNS) metastasis is present;
• Toxicity from previous antitumor therapy did not return to grade 1 or baseline levels (CTCAE version 5.0);
• Accompanied or prior to interstitial lung disease or interstitial pneumonia;
• Uncontrolled metabolic disorders, such as those in patients with diabetes (glycated hemoglobin ≥8.5%), or secondary reactions to other non-malignant organ or systemic diseases or cancer, which can lead to higher medical risks and/or uncertainties in survival assessment;
• An autoimmune disease that is active or has previously suffered from and is likely to recur;
• Uncontrolled comorbidities include but are not limited to uncontrolled hypertension (systolic blood pressure ≥160mmHg and/or diastolic blood pressure ≥100mmHg) or any unstable cardiovascular and cerebrovascular diseases that occurred within 6 months prior to treatment enrollment;
• Ultrasound indicates the separation of peritoneal effusion;
• Patients with intestinal obstruction;
• Patients with comorbidities or active autoimmune diseases that require the use of glucocorticoids or other immunosuppressive drugs during the trial period, excluding local transdermal absorption of glucocorticoids (i.e., no more than 5mg/ day of prednisone or equivalent doses of other glucocorticoids);
• Women who are pregnant or breastfeeding.

Sponsors & Collaborators

• Beijing Geekgene Technology Co., LTD: lead
• Beijing GoBroad Hospital: collaborator

Study Sites (1)

Beijing GoBroad Hospital

Beijing, China

RECRUITING

MeSH Terms

Conditions

Stomach Neoplasms

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases

Central Study Contacts

Changsong Qi, MD, PhD

CONTACT

+86-13811394004; changsongqi@bjmu.edu.cn

Xu Zhang, PhD

CONTACT

+86-13482323610; zhangx@geekgene.cn

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 7, 2026
• First Posted: January 30, 2026
• Study Start: September 16, 2025
• Primary Completion (Estimated): December 17, 2026
• Study Completion (Estimated): December 17, 2027
• Last Updated: January 30, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)